Cargando…

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

Successes with anti-CD20 antibodies in chronic lymphocytic leukemia (CLL) and enhanced activity of Fc-engineered vs unmodified antibody therapy suggest a potentially impactful role for natural killer (NK) cells and other innate immune cells in controlling this disease. Stimulated NK cells have shown...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yano, Max, Sharpe, Chia, Lance, J. Rachel, Ravikrishnan, Janani, Zapolnik, Kevan, Mo, Xiaokui, Woyach, Jennifer A., Sampath, Deepa, Kittai, Adam S., Vasu, Sumithira, Bhat, Seema, Rogers, Kerry A., Lee, Dean A., Muthusamy, Natarajan, Byrd, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582588/ https://www.ncbi.nlm.nih.gov/pubmed/35486482 http://dx.doi.org/10.1182/bloodadvances.2021005883

Ejemplares similares

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia
por: Lai, Tzung-Huei, et al.
Publicado: (2022)

CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway
por: Browning, Rebekah L., et al.
Publicado: (2015)

Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential
por: Yano, Max, et al.
Publicado: (2022)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34(+)CD123(+) cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
por: Mani, Rajeswaran, et al.
Publicado: (2018)

Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia
por: Gopalakrishnan, Bhavani, et al.
Publicado: (2018)

P1269: VIP152 IS A NOVEL CDK9 INHIBITOR WITH IMPROVED SELECTIVITY, TARGET MODULATION, AND CARDIAC SAFETY IN PATIENTS WITH LYMPHOMA
por: Frigault, M., et al.
Publicado: (2022)

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
por: Sher, Steven, et al.
Publicado: (2022)

Optimizing extracellular vesicles’ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant
por: Elgamal, Sara, et al.
Publicado: (2021)

The role of NK cells in HIV-1 protection: autologous, allogeneic or both?
por: Hens, Jef, et al.
Publicado: (2016)

Efficacy of adoptive transfer of expanded fetal liver-derived precursor syngeneic and allogeneic murine NK cells against solid tumors
por: Liang, Xiaoyan, et al.
Publicado: (2015)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy
por: Schoettler, Michelle L., et al.
Publicado: (2023)

Tetraspanins as therapeutic targets in hematological malignancy: a concise review
por: Beckwith, Kyle A., et al.
Publicado: (2015)

Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience
por: Jiang, Justin, et al.
Publicado: (2022)

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
por: Buddingh, Emilie P., et al.
Publicado: (2011)

Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023)

One‐Step Method for Instant Generation of Advanced Allogeneic NK Cells
por: Lee, Daniel Y., et al.
Publicado: (2018)

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
por: Li, Feng, et al.
Publicado: (2020)

Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1
por: Kruse, Vanessa, et al.
Publicado: (2015)

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019
por: Kittai, Adam S., et al.
Publicado: (2022)

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
por: Sigmund, Audrey M., et al.
Publicado: (2022)

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells
por: Ojo, Evelyn O., et al.
Publicado: (2019)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation
por: Park, Ki Hyun, et al.
Publicado: (2020)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model
por: Motiwala, Tasneem, et al.
Publicado: (2014)

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
por: Berning, Philipp, et al.
Publicado: (2023)

HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy
por: Hoerster, Keven, et al.
Publicado: (2021)

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors
por: Sanchez-Martinez, Diego, et al.
Publicado: (2018)

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
por: Gornalusse, Germán G., et al.
Publicado: (2017)

Natural killer (NK) activity of porcine blood lymphocytes against allogeneic melanoma target cells
por: Büttner, Mathias, et al.
Publicado: (1991)

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation
por: Meissner, Julia, et al.
Publicado: (2022)

Combination of Expanded Allogeneic NK Cells and T Cell-Based Immunotherapy Exert Enhanced Antitumor Effects
por: Wang, Xiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iocvkprb1n61fc65f54vedestn